ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02484638
Recruitment Status : Terminated (Business decision non-safety related.)
First Posted : June 29, 2015
Last Update Posted : November 27, 2018
Sponsor:
Information provided by (Responsible Party):
CSL Behring

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : March 28, 2018
  Actual Study Completion Date : March 28, 2018